目的:系统评价5-氨基酮戊酸光动力疗法(ALA-PDT)对宫颈高危型人乳头瘤病毒(HR-HPV)感染治疗的疗效和安全性。方法:计算机检索PubMed、Web of Science、Embase、Ovid MEDLINE、EBM Reviews—Cochrane Central Register of Con trolled Tr...目的:系统评价5-氨基酮戊酸光动力疗法(ALA-PDT)对宫颈高危型人乳头瘤病毒(HR-HPV)感染治疗的疗效和安全性。方法:计算机检索PubMed、Web of Science、Embase、Ovid MEDLINE、EBM Reviews—Cochrane Central Register of Con trolled Trials、中国知网(CNKI)、中文科技期刊数据库(VIP)和万方数据库(wanfang database)中的随机对照试验。依照事先制定的纳入标准和排除标准对文献进行筛选、数据提取和质量评价,应用Revman 5.3进行统计分析。结果:共纳入11篇文献,Meta分析结果显示,ALA-PDT治疗后3、6、9及12个月的HPV转阴率分别是对照组的3.5、4.12、2.28及2.4倍。结论:ALA-PDT治疗宫颈HR-HPV感染不仅疗效明显,且治疗结果较稳定,值得临床推广与应用。展开更多
Objective:Traditional Chinese medicine plays a significant role in the treatment of the pandemic of coronavirus disease 2019(COVID-19).Tanreqing Capsule(TRQC)was used in the treatment of COVID-19 patients in the Shang...Objective:Traditional Chinese medicine plays a significant role in the treatment of the pandemic of coronavirus disease 2019(COVID-19).Tanreqing Capsule(TRQC)was used in the treatment of COVID-19 patients in the Shanghai Public Health Clinical Center.This study aimed to investigate the clinical efficacy of TRQC in the treatment of COVID-19.Methods:A retrospective cohort study was conducted on 82 patients who had laboratory-confirmed mild and moderate COVID-19;patients were treated with TRQC in one designated hospital.The treatment and control groups consisted of 25 and 57 cases,respectively.The treatment group was given TRQC orally three times a day,three pills each time,in addition to conventional Western medicine treatments which were also administered to the control group.The clinical efficacy indicators,such as the negative conversion time of pharyngeal swab nucleic acid,the negative conversion time of fecal nucleic acid,the duration of negative conversion of pharyngeal-fecal nucleic acid,and the improvement in the level of immune indicators such as T-cell subsets(CD3,CD4 and CD45)were monitored.Results:COVID-19 patients in the treatment group,compared to the control group,had a shorter negative conversion time of fecal nucleic acid(4 vs.9 days,P=0.047)and a shorter interval of negative conversion of pharyngeal-fecal nucleic acid(0 vs.2 days,P=0.042).The level of CD3+T cells increased in the treatment group compared to the control group([317.09±274.39]vs.[175.02±239.95]counts/l L,P=0.030).No statistically significant differences were detected in the median improvement in levels of CD4+T cells(173 vs.107 counts/l L,P=0.208)and CD45+T cells(366 vs.141 counts/l L,P=0.117)between the treatment and control groups.Conclusion:Significant reductions in the negative conversion time of fecal nucleic acid and the duration of negative conversion of pharyngeal-fecal nucleic acid were identified in the treatment group as compared to the control group,illustrating the potential therapeutic benefits of using TRQC as a complement to conventional medicine in patients with mild and moderate COVID-19.The underlying mechanism may be related to the improved levels of the immune indicator CD3+T cells.展开更多
文摘目的:系统评价5-氨基酮戊酸光动力疗法(ALA-PDT)对宫颈高危型人乳头瘤病毒(HR-HPV)感染治疗的疗效和安全性。方法:计算机检索PubMed、Web of Science、Embase、Ovid MEDLINE、EBM Reviews—Cochrane Central Register of Con trolled Trials、中国知网(CNKI)、中文科技期刊数据库(VIP)和万方数据库(wanfang database)中的随机对照试验。依照事先制定的纳入标准和排除标准对文献进行筛选、数据提取和质量评价,应用Revman 5.3进行统计分析。结果:共纳入11篇文献,Meta分析结果显示,ALA-PDT治疗后3、6、9及12个月的HPV转阴率分别是对照组的3.5、4.12、2.28及2.4倍。结论:ALA-PDT治疗宫颈HR-HPV感染不仅疗效明显,且治疗结果较稳定,值得临床推广与应用。
基金supported by Emergency Scientific Research Project of Shanghai Health Committee and Shanghai Administration of Traditional Chinese Medicine(No.2020YJ01)Shanghai Key Laboratory of Traditional Chinese Clinical Medicine(No.14DZ2273200)Shanghai Key Clinical Specialty(No.SHSLCZDZK05101)。
文摘Objective:Traditional Chinese medicine plays a significant role in the treatment of the pandemic of coronavirus disease 2019(COVID-19).Tanreqing Capsule(TRQC)was used in the treatment of COVID-19 patients in the Shanghai Public Health Clinical Center.This study aimed to investigate the clinical efficacy of TRQC in the treatment of COVID-19.Methods:A retrospective cohort study was conducted on 82 patients who had laboratory-confirmed mild and moderate COVID-19;patients were treated with TRQC in one designated hospital.The treatment and control groups consisted of 25 and 57 cases,respectively.The treatment group was given TRQC orally three times a day,three pills each time,in addition to conventional Western medicine treatments which were also administered to the control group.The clinical efficacy indicators,such as the negative conversion time of pharyngeal swab nucleic acid,the negative conversion time of fecal nucleic acid,the duration of negative conversion of pharyngeal-fecal nucleic acid,and the improvement in the level of immune indicators such as T-cell subsets(CD3,CD4 and CD45)were monitored.Results:COVID-19 patients in the treatment group,compared to the control group,had a shorter negative conversion time of fecal nucleic acid(4 vs.9 days,P=0.047)and a shorter interval of negative conversion of pharyngeal-fecal nucleic acid(0 vs.2 days,P=0.042).The level of CD3+T cells increased in the treatment group compared to the control group([317.09±274.39]vs.[175.02±239.95]counts/l L,P=0.030).No statistically significant differences were detected in the median improvement in levels of CD4+T cells(173 vs.107 counts/l L,P=0.208)and CD45+T cells(366 vs.141 counts/l L,P=0.117)between the treatment and control groups.Conclusion:Significant reductions in the negative conversion time of fecal nucleic acid and the duration of negative conversion of pharyngeal-fecal nucleic acid were identified in the treatment group as compared to the control group,illustrating the potential therapeutic benefits of using TRQC as a complement to conventional medicine in patients with mild and moderate COVID-19.The underlying mechanism may be related to the improved levels of the immune indicator CD3+T cells.
